Want to see HK:2496 full AI Analyst Report?
Top Page
Wuhan YZY Biopharma Co., Ltd. Class H
(2496)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$3.50
▼(-55.47% Downside)
Action:Reiterated
Date:04/21/26
The score is mainly weighed down by weak financial performance (sharp 2025 revenue decline, severe margin compression, persistent losses, and negative equity), indicating elevated solvency and funding risk despite improved 2025 cash burn. Technicals add pressure as the stock trades below key longer-term moving averages with negative MACD. Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Improving cash burn
The company materially reduced cash burn in 2025 versus 2024, cutting operating and free cash outflows by roughly fourfold. That reflects tighter spending or working-capital relief and meaningfully lowers near-term fundraising pressure, improving runway if the trend persists.
Negative Factors
Sharp revenue decline
A steep 56.4% revenue drop in 2025 signals significant demand, commercialization, or product-mix disruption. Such volatility undermines predictable cash generation and makes planning, R&D investment and debt servicing more difficult absent a durable recovery in top-line trends.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash burn
The company materially reduced cash burn in 2025 versus 2024, cutting operating and free cash outflows by roughly fourfold. That reflects tighter spending or working-capital relief and meaningfully lowers near-term fundraising pressure, improving runway if the trend persists.
Read all positive factors
Wuhan YZY Biopharma Co., Ltd. Class H (2496) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$736.63M
Dividend YieldN/A
Average Volume (3M)933.00
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth-38.07%
EPS Growth13.45%
CountryHK
Employees113
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding179,479,110
10 Day Avg. Volume80
30 Day Avg. Volume933
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)-26.32
Price to Sales (P/S)21.44
P/FCF Ratio-62.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wuhan YZY Biopharma Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic co...
How the Company Makes Money
null...
Wuhan YZY Biopharma Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.13M | 107.81M | 11.92M | 2.26M | 12.18M |
| Gross Profit | 6.17M | 85.07M | 11.92M | 2.26M | 12.18M |
| EBITDA | -83.65M | -86.95M | -158.39M | -169.23M | -125.20M |
| Net Income | -82.54M | -97.60M | -190.98M | -188.87M | -148.52M |
Balance Sheet | |||||
| Total Assets | 175.08M | 267.84M | 301.62M | 265.92M | 163.33M |
| Cash, Cash Equivalents and Short-Term Investments | 100.11M | 126.28M | 196.68M | 200.52M | 83.71M |
| Total Debt | 127.81M | 127.35M | 90.11M | 67.32M | 28.48M |
| Total Liabilities | 228.13M | 237.31M | 173.97M | 129.05M | 46.51M |
| Stockholders Equity | -53.05M | 30.54M | 127.65M | 155.88M | 143.16M |
Cash Flow | |||||
| Free Cash Flow | -22.46M | -102.22M | -187.95M | -156.40M | -82.10M |
| Operating Cash Flow | -21.57M | -100.72M | -186.02M | -155.16M | -80.55M |
| Investing Cash Flow | -130.00K | -4.67M | 54.81M | 5.10M | -16.27M |
| Financing Cash Flow | -4.68M | 33.02M | 176.29M | 241.33M | 81.03M |
Wuhan YZY Biopharma Co., Ltd. Class H Technical Analysis
Negative
7.86
Price Trends
4.49
Negative
5.19
Negative
6.11
Negative
Market Momentum
-0.22
Negative
13.38
Positive
39.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2496, the sentiment is Negative. The current price of 7.86 is above the 20-day moving average (MA) of 4.01, above the 50-day MA of 4.49, and above the 200-day MA of 6.11, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 13.38 is Positive, neither overbought nor oversold. The STOCH value of 39.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2496.
Wuhan YZY Biopharma Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.63B | 26.73 | 43.89% | ― | 150.60% | ― | |
46 Neutral | HK$830.08M | -2.84 | -14.48% | ― | ― | 55.86% | |
43 Neutral | HK$736.63M | -6.86 | 485.24% | ― | -38.07% | 13.45% | |
43 Neutral | HK$629.95M | -3.00 | -27.04% | ― | -20.21% | 2.98% | |
42 Neutral | HK$574.36M | -4.19 | -28.13% | ― | -33.80% | 31.52% | |
41 Neutral | HK$970.43M | -10.26 | -16.53% | ― | ― | ― |
* Healthcare Sector Average
HK:2496
Wuhan YZY Biopharma Co., Ltd. Class H
3.80
-1.10
-22.45%
HK:2137
Brii Biosciences Limited
1.15
-0.60
-34.29%
HK:1244
3D Medicines, Inc.
2.44
-2.71
-52.62%
HK:2181
Mabpharm Limited
0.40
-0.10
-21.00%
HK:6628
Transcenta Holding Limited
1.29
-0.36
-21.82%
HK:2898
Sunho Biologics,Inc.
6.39
0.83
14.93%
Wuhan YZY Biopharma Co., Ltd. Class H Corporate Events
Wuhan YZY Biopharma AGM Approves 2025 Results, Profit Plan and Auditor Reappointment
Jun 29, 2026
Wuhan YZY Biopharma reported that its annual general meeting, held on June 29, 2026 in Wuhan, was duly convened in compliance with PRC laws, Hong Kong Listing Rules and the company’s articles, with all directors attending on-site or online. ...
Wuhan YZY Biopharma Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate
Jun 8, 2026
Wuhan YZY Biopharma Co., Ltd. has called its annual general meeting for June 29, 2026 in Wuhan, where shareholders will review and approve the company’s 2025 annual report, board and supervisory committee reports, financial statements, and p...
YZY Biopharma’s M701 Shows Promising Phase III Data Ahead of 2026 ASCO
May 22, 2026
Wuhan YZY Biopharma announced that new clinical data on its core bispecific antibody M701 will be presented at the 2026 American Society of Clinical Oncology Annual Meeting, underscoring its ambitions in advanced cancer care. The drug, a national ...
Wuhan YZY Biopharma Reshapes Supervisory Committee With New Employee Representative
May 15, 2026
Wuhan YZY Biopharma announced that employee representative supervisor Dr. Shi Jian has resigned effective May 15, 2026, citing personal career development reasons and confirming no disagreements with the board or issues requiring shareholder atten...
YZY Biopharma’s Lead Cancer Bispecific M701 Wins NMPA NDA Acceptance
May 7, 2026
Wuhan YZY Biopharma Co., Ltd., a Chinese biotechnology company specializing in bispecific antibody-based cancer therapies, is advancing a pipeline centered on T cell-engaging and tumor microenvironment-targeted biologics. Its lead candidate M701 i...
YZY Biopharma’s M701 Data Secured for High-Profile ASCO 2026 Presentations
Apr 23, 2026
Wuhan YZY Biopharma Co., Ltd. announced that two clinical studies of its core bispecific antibody M701 have been selected for presentation at the 2026 American Society of Clinical Oncology Annual Meeting. The drug targets malignant serous cavity e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.